BibTex RIS Cite

Serum adipocytokine levels in patients with colorectal cancer

Year 2010, Volume: 37 Issue: 4, 321 - 325, 01.12.2010

Abstract

Objectives: Adipose tissue, besides its main function as an energy storage depot, is currently considered an en­docrine organ that secretes several self-produced cytok­ines. Leptin and resistin play an important role in energy homeostasis, glucose, lipid metabolism and regulation of body weight. The aim of the current study was to deter­mine the concentration of leptin and resistin in pre-opera­tional and post-operational periods of patients diagnosed as colorectal cancer. Materials and methods: The body mass index (BMI) and values of leptin and resistin in blood at diagnosis were measured in 12 colorectal cancer patients in pre- and post-operational periods and in 12 age- and sex-matched controls. Serum leptin and resistin concentrations were measured by ELISA method. Results: Decreased leptin (1.95±0.62 ng/ml) and resis­tin (4.32±1.83 ng/ml) levels were found in pre-operational group compared with the control group (leptin: 6.12±0.82 ng/ml; resistin: 10.75±1.46 ng/ml) (p

References

  • Caan BJ, Coates AO, Slattery ML, Potter JD, Qusenberr CP, Edwards SM. Body size and the risk of colon cancer in large case-control study. Int J Obes 1998;22:178-84.
  • Housa D, Housava J, Vernerova Z, Haluzik M. Adipocytok- ines and cancer. Physiol Res 2006;55:233-44.
  • Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
  • Baratta M. Leptin from a signal of adiposity to a hormone mediator in peripheral tissues. Med Sci Monit 2002;8:282– 92.
  • Friedman JM, Halaas J. Leptin and the regulation of body weight in mammals. Nature 1998;22:763–70.
  • Ukkola O. Resistin a mediator of obesity associated insu- lin resistance or an innocent bystander. Eur J Endocrinol 2002;147:571–4.
  • Kumor A, Daniel P, Pietruczuk M, Małecka PE. Serum lep- tin, adiponectin, and resistin concentration in colorectal ad- enoma and carcinoma (CC) patients. Int J Colorectal Dis 2009;24:275–81.
  • Arpaci F, Yılmaz MI, Ozet A, ve ark. Low serum leptin level in colon cancer patients without significant weight loss. Tu- mori 2002;88:147-9.
  • Simone ND, Nicuolo FD, Sanguinetti M, et al. Resistin regulates human choriocarcinoma cell invasive behavior and endothelial cell angiogenic processes. J Endocrinol 2006;189:691-9.
  • Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkan- tonis I, Gratsias I, Syrigos KN. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008;61:391-7.
  • Meier U, Gressner AM. Endocrine regulation of energy me- tabolism: review of pathobiochemical and clinical chemi- cal aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511—25.
  • Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponec- tin for colorectal adenoma, and resistin and visfatin for col- orectal cancer. Cancer Sci 2010;101:1286-91.
  • Bolukbas F, Kilic H, Bolukbas C, ve ark. Serum leptin con- centration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 2004;4:29-33.
  • Simons JP, Schols AM, Campfirld L.A et al. Plasma con- centration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 1997;93:273–7.
  • Wallace AM, Sattar N, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentra- tion in gastrointestinal cancer patients. Clin Cancer Res 1998;4:2977–9.
  • Hardwick JC, Van Der Brink GR, Offerhause GJ. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001;121:79–90.
  • Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2005;207:12–22.
  • Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as bio- markers of gastric cancer. J Gastroenterol 2009;44:685–90.
  • Dalamaga M, Karmaniolas K, Nikolaidou A, et al. Adiponec- tin and resistin are associated with risk for myelodysplas- tic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 2008;44:1744–53.
  • Dalamaga M, Karmaniolas K, Panagiotou A, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case control study. Canc Causes Contr 2009;20:193-9.
  • Silswal N, Singh A.K, Aruna B, et al. Human resistin stimu- lates the pro-inflammatory cytokines TNF alpha and IL-12 in macrophages by NFkappaB dependent pathway. Bio- chem Biophys Res Commun 2005;334:1092–101.

Kolerektal kanserli hastalarda serum adipositokin düzeyleri

Year 2010, Volume: 37 Issue: 4, 321 - 325, 01.12.2010

Abstract

Amaç: Yağ dokusu, bir enerji deposu olan ana işlevinin yanında, bazı sitokinler salgılayarak bir endokrin organ olarak kabul edilir. Leptin ve rezistin, enerji homeostazi­sinde, glikoz, lipid metabolizmasında ve vücut ağırlığının düzenlenmesinde önemli bir rol oynamaktadır. Bu çalış­manın amacı, kolorektal kanserli hastalarda operasyon öncesi ve operasyon sonrası dönemlerde leptin ve rezis­tin konsantrasyonlarının belirlenmesidir. Gereç ve yöntem: Toplam 12 kolorektal kanserli hastada ameliyet öncesi ve sonrası dönemde ve yaş ve cinsiyet uyumlu 12 kişiden oluşan kontrol grubunda vücut kitle in­deksi (VKİ) ve kan örneklerinde leptin ve rezistin düzeyleri ölçüldü. Serum leptin ve rezistin konsantrasyonları ELISA ile yöntemi ile ölçüldü. Bulgular: Operasyon öncesi grup (leptin: 1.95±0.62 ng/ml; resistin 4.32±1.83 ng/ml) kontrol grubuna (leptin: 6.12±0.82 ng/ml; resistin: 10.75±1.46 ng/ml) göre karşı­laştırıldığında leptin ve rezistin düzeylerinde azalma göz­lemlendi (sırasıyla, p

References

  • Caan BJ, Coates AO, Slattery ML, Potter JD, Qusenberr CP, Edwards SM. Body size and the risk of colon cancer in large case-control study. Int J Obes 1998;22:178-84.
  • Housa D, Housava J, Vernerova Z, Haluzik M. Adipocytok- ines and cancer. Physiol Res 2006;55:233-44.
  • Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
  • Baratta M. Leptin from a signal of adiposity to a hormone mediator in peripheral tissues. Med Sci Monit 2002;8:282– 92.
  • Friedman JM, Halaas J. Leptin and the regulation of body weight in mammals. Nature 1998;22:763–70.
  • Ukkola O. Resistin a mediator of obesity associated insu- lin resistance or an innocent bystander. Eur J Endocrinol 2002;147:571–4.
  • Kumor A, Daniel P, Pietruczuk M, Małecka PE. Serum lep- tin, adiponectin, and resistin concentration in colorectal ad- enoma and carcinoma (CC) patients. Int J Colorectal Dis 2009;24:275–81.
  • Arpaci F, Yılmaz MI, Ozet A, ve ark. Low serum leptin level in colon cancer patients without significant weight loss. Tu- mori 2002;88:147-9.
  • Simone ND, Nicuolo FD, Sanguinetti M, et al. Resistin regulates human choriocarcinoma cell invasive behavior and endothelial cell angiogenic processes. J Endocrinol 2006;189:691-9.
  • Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkan- tonis I, Gratsias I, Syrigos KN. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008;61:391-7.
  • Meier U, Gressner AM. Endocrine regulation of energy me- tabolism: review of pathobiochemical and clinical chemi- cal aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511—25.
  • Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponec- tin for colorectal adenoma, and resistin and visfatin for col- orectal cancer. Cancer Sci 2010;101:1286-91.
  • Bolukbas F, Kilic H, Bolukbas C, ve ark. Serum leptin con- centration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 2004;4:29-33.
  • Simons JP, Schols AM, Campfirld L.A et al. Plasma con- centration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 1997;93:273–7.
  • Wallace AM, Sattar N, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentra- tion in gastrointestinal cancer patients. Clin Cancer Res 1998;4:2977–9.
  • Hardwick JC, Van Der Brink GR, Offerhause GJ. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001;121:79–90.
  • Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2005;207:12–22.
  • Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as bio- markers of gastric cancer. J Gastroenterol 2009;44:685–90.
  • Dalamaga M, Karmaniolas K, Nikolaidou A, et al. Adiponec- tin and resistin are associated with risk for myelodysplas- tic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 2008;44:1744–53.
  • Dalamaga M, Karmaniolas K, Panagiotou A, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case control study. Canc Causes Contr 2009;20:193-9.
  • Silswal N, Singh A.K, Aruna B, et al. Human resistin stimu- lates the pro-inflammatory cytokines TNF alpha and IL-12 in macrophages by NFkappaB dependent pathway. Bio- chem Biophys Res Commun 2005;334:1092–101.
There are 21 citations in total.

Details

Primary Language Turkish
Journal Section Research Articles
Authors

Serdar Erkasap This is me

Eda Özçelik This is me

Sema Uslu This is me

Mehmet Kara This is me

Nilüfer Erkasap This is me

Publication Date December 1, 2010
Submission Date March 2, 2015
Published in Issue Year 2010 Volume: 37 Issue: 4

Cite

APA Erkasap, S., Özçelik, E., Uslu, S., Kara, M., et al. (2010). Kolerektal kanserli hastalarda serum adipositokin düzeyleri. Dicle Medical Journal, 37(4), 321-325.
AMA Erkasap S, Özçelik E, Uslu S, Kara M, Erkasap N. Kolerektal kanserli hastalarda serum adipositokin düzeyleri. diclemedj. December 2010;37(4):321-325.
Chicago Erkasap, Serdar, Eda Özçelik, Sema Uslu, Mehmet Kara, and Nilüfer Erkasap. “Kolerektal Kanserli Hastalarda Serum Adipositokin düzeyleri”. Dicle Medical Journal 37, no. 4 (December 2010): 321-25.
EndNote Erkasap S, Özçelik E, Uslu S, Kara M, Erkasap N (December 1, 2010) Kolerektal kanserli hastalarda serum adipositokin düzeyleri. Dicle Medical Journal 37 4 321–325.
IEEE S. Erkasap, E. Özçelik, S. Uslu, M. Kara, and N. Erkasap, “Kolerektal kanserli hastalarda serum adipositokin düzeyleri”, diclemedj, vol. 37, no. 4, pp. 321–325, 2010.
ISNAD Erkasap, Serdar et al. “Kolerektal Kanserli Hastalarda Serum Adipositokin düzeyleri”. Dicle Medical Journal 37/4 (December 2010), 321-325.
JAMA Erkasap S, Özçelik E, Uslu S, Kara M, Erkasap N. Kolerektal kanserli hastalarda serum adipositokin düzeyleri. diclemedj. 2010;37:321–325.
MLA Erkasap, Serdar et al. “Kolerektal Kanserli Hastalarda Serum Adipositokin düzeyleri”. Dicle Medical Journal, vol. 37, no. 4, 2010, pp. 321-5.
Vancouver Erkasap S, Özçelik E, Uslu S, Kara M, Erkasap N. Kolerektal kanserli hastalarda serum adipositokin düzeyleri. diclemedj. 2010;37(4):321-5.